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A series of studies has shown that Helicobacter pylori eradication induces remission in most patients with low-grade gastric mucosa-
associated lymphoid tissue (MALT) lymphoma. However, there have been few reports about the effect of bacterial treatment on the
gastric MALT lymphoma in Korea, a well-known H. pylori endemic area. A total of 111 H. pylori-infected patients were prospectively
enrolled in Seoul National University Hospital and 99 among them were completely followed up according to our protocol. After
H. pylori eradication, tumoural response was evaluated by endoscopy and histopathology every 2–3 months till complete remission
(CR) and every 6 months after achieving CR. Median follow-up period was 41 months (range, 11–125 months). Helicobacter pylori
was successfully eradicated in all 99 patients and CR was obtained in 84 (84.8%) of 99 patients. The median time to reach CR was 3
months and 94% of CR is in continuous complete remission. Five patients with CR relapsed after 10–22 months without the
evidence of H. pylori reinfection. Cumulative recurrence rate was 2.3, 7.7 and 9.3% at 1, 2 and 3 years, respectively. Tumours were
mainly located in distal stomach (67.7%) and tumours in distal stomach were associated with more favourable response than those in
proximal stomach (P¼0.001). Majority of patients with low-grade gastric MALT lymphoma treated by exclusive H. pylori eradication
have a favourable long-term outcome, offering a real chance of cure. Tumour location could be a predictive factor for remission
following H. pylori eradication.
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Recently, Helicobacter pylori eradication is considered well-
accepted initial therapy in cases of localised (stage I) low-grade
gastric mucosa-associated lymphoid tissue (MALT) lymphoma, in
which recently published series confirmed 62–95% complete
remission (CR) rate (Neubauer et al, 1997; Savio et al, 2000;
Montalban et al, 2001; Fischbach et al, 2004; Wundisch et al, 2005).
The variation of CR rates may be due to the heterogeneity of
previous studies, particularly as regards of study design and
clinical characteristics. Data in some articles are lacking regarding
H. pylori infection status and/or tumour extension and stage. Our
study addressed these issues by strict study design, which
comprised precise inclusion criteria, complete tumour staging
and meticulous endoscopic follow-up.
In stage-I cases, the depth of invasion seems to be a predictive
factor because previous studies have shown the evidence that
tumours that invade muscularis propria or beyond are more likely
not to respond to eradication therapy than those restricted to
submucosa (Sackmann et al, 1997; Steinbach et al, 1999; Ruskone-
Fourmestraux et al, 2001). However, clinical determination of the
depth of invasion is not perfect without the evaluation of a surgical
specimen. Therefore, there remains a need for alternative
prognostic markers for stage-I gastric MALT lymphomas at
diagnosis. The aim of this large prospective single-centre study
was to determine the long-term outcome of exclusive H. pylori
eradication therapy on low-grade stage-I gastric MALT lymphoma
and to define the predictive factors of clinical response.
PATIENTS AND METHODS
Patients and diagnostic criteria
From January 1996 to December 2006, consecutive patients with
H. pylori-positive stage-I (Lugano classification) (Rohatiner et al,
1994) low-grade gastric MALT lymphoma were prospectively
enrolled in single centre (Seoul National University Hospital). The
diagnosis of low-grade gastric MALT lymphoma was made
according to the criteria of Isaacson and the recently published
World Health Organization (WHO) classification of lymphoid
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MALT type.
Initial stage work-up and H. pylori eradication therapy
Complete staging work-up (de Jong et al, 1999; Raderer et al, 2000)
consisted of the detailed physical examination, chest X-ray,
abdomen CT, endoscopic ultrasonography (EUS) and bilateral
bone marrow examination. Due to a lack of availability in early
period, EUS could not be performed in 28 cases.
H. pylori infection status was determined by histologic
examination and rapid urease test (CLOt, Delta West, Bentley,
Western Australia). Helicobacter pylori status was considered to be
positive if any of the two tests was positive. Only patients with
H. pylori-positive and stage-I gastric MALT lymphoma were
enrolled in the study. All patients were assigned to the 7-day
course of omeprazole (20mg b.i.d.), amoxicillin (1000mg b.i.d.)
and clarithromycin (500mg b.i.d.). Second-line therapy consisted
of a quadruple regimen containing omeprazole 20mg b.i.d.,
tripotassium dicitrate bismuthate 300mg q.i.d., metronidazole
500mg t.i.d. and tetracycline 500mg q.i.d. for 7 days.
Remission evaluation following H. pylori eradication
Response was assessed according to the WHO criteria: CR was
defined as no macroscopic tumour, histologically confirmed; a
partial response when at least 50% tumour reduction was found;
stable disease in case of variation within either 50% decrease of
25% increase; and progressive disease when an increase of at least
25% was present (Wotherspoon et al, 1993). Treatment was
considered to have failed if patients showed no improvement or
did not meet criteria for CR within 1 year after H. pylori
eradication.
Patients first underwent follow-up endoscopy at 4–8 weeks after
the completion of antibiotic therapy for the evaluation of H. pylori
eradication. For determination of the clinical response, endoscopy
with multiple biopsies from tumours and suspicious areas was
performed at 2–3 months after the confirmation of eradication.
Then follow-up endoscopy was repeated every 2–3 months until
CR was achieved or until treatment failure for 1 year. In cases with
CR, endoscopic examination and biopsy were performed every 6
months and the median number of endoscopies the patients in CR
was nine. At each follow-up endoscopic examination, two separate
biopsies from macroscopically normal mucosa of the antrum and
body were evaluated for H. pylori infection. In cases of treatment
failure to H. pylori eradication, patients were referred for surgery
or radiation therapy (Figure 1).
Statistical analysis
Data are expressed as median with range. In between-group
comparisons, continuous variables were analysed by the Student’s
t-test and categorical variables using the w
2-test or Fisher’s exact
test. The Kaplan–Meier method was used to estimate remission
duration. Analyses were performed using the Statistical Package
for the Social Sciences (version 12.0; SPSS INC. Chicago, IL, USA).
All statistical tests were two-sided, and a value of P o0.05 was
considered to be statistically significant.
RESULTS
Clinicopathologic and endoscopic characteristics
A total of 111 patients were enrolled initially and 12 patients did
not complete our protocol. Finally, 99 of the patients (M:F, 41:58;
age median 52 years (24–77 years)) were evaluated in this study.
There were fewer male than female patients and the male to female
ratio was 1:1.4.
The macroscopic tumour type was determined according to the
classification of Watanabe with minor modifications, as follows
(Watanabe, 1980): (i) protruding, mass-like (9.1%); (ii) granular,
gastritis-like (19.2%); (iii) depressed, erosion (50.5%); (iv)
excavated, ulceration (15.2%); and (v) mixed (6.1%). The
neoplasm was located in the distal stomach (antrum, angle and
low body) in 67.7%. The depth of lymphoma involvement in the
gastric wall was determined by EUS in 67 patients and by
histologic examination of surgically resected specimen in 14
patients; most of the cases confined to the musoca (55.6%) or
submucosa (34.6%) (Table 1).
NC/PD
Hp-positive stage IE low-grade gastric MALT
Eradication of Hp
1st endoscopy
2nd endoscopy
Hp (-) Hp (+) 
Re-Hp treatment
PR CR
Endoscopy q 6 months Op/RT 
4–8th week 
2–3th months
Endoscopy q 2–3 months till CR 
CR NC/PD till 1 year
Endoscopy q 6 months  Op/RT 
Figure 1 Schematic study design for the treatment approach and follow-
up of patients with H. pylori-positive early-stage low-grade gastric MALT
lymphoma. Hp¼Helicobacter pylori; MALT¼mucosa-associated lymphoid
tissue; CR¼complete remission; NC¼no change; PR¼partial response;
Op¼operation; RT¼radiation therapy.
Table 1 Clinical and endoscopic characteristics (n¼99)
Clinicopathologic characteristics No. of patients %
Age, median (range), years 52 (24–77)
Sex (male:female) 41:58
Endoscopic appearance
I: protruding, mass 9 9.1
II: granular, gastritis 19 19.2
III: depressed, erosion 50 50.5
IV: excavated, ulceration 15 15.2
V: mixed 6 6.1
Endoscopic location
Proximal
a 29 29.3
Distal
b 67 67.7
Multifocal 3 3.0
Depth of gastric wall involvement
c
Mucosa 45/81 55.6
Submucosa 28/81 34.6
Muscularis propria or beyond 8/81 9.9
aMid body, high body, fundus or cardia.
bAntrum, angle or low body.
cEvaluated by
EUS in 67 patients and by histologic examination of surgical specimen in 14 patients.
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Cure of H. pylori infection was documented in all patients (99 out
of 99); eight patients needed a second-line treatment for successful
eradication.
Median follow-up period was 41 months (11–125 months).
Long-term outcome was characterised by CR of lymphoma in 84
out of 99 cases (84.8%). The median time to get CR after the
completion of antibiotic therapy in H. pylori-eradicated patients
was 3 months (1–20 months).
Table 2 shows the probabilities of CR stratified by clinicopatho-
logic factors. The depth of tumour invasion determined by EUS or
surgery strongly correlated with the outcome of eradication
therapy. Complete remission was observed in 62 out of 73
(84.9%) patients with tumours that were limited to the mucosa
or submucosa, but only in four out of eight (50.0%) patients with
tumours that had invaded the muscularis propria or beyond
(P¼0.031). Interestingly, in our analysis, anatomic location in the
stomach also influenced the tumour response. Patients with distal
tumours had a higher CR rate (92.5%) than patients with proximal
tumours (65.5%) (P¼0.001). We analysed other clinical char-
acteristics (age, sex, performance status, levels of haemoglobin,
LDH and b2-microglobulin at diagnosis) that showed no
statistically significant associations with the clinical response.
Fifteen patients (15.2%) showed persistent disease at 12 months
after the eradication therapy. They underwent operation or
radiation therapy and had CR in the subsequent follow-up
(Figure 2).
Recurrence of MALT lymphoma and reinfection of H.
pylori during follow-up
During median follow-up of 41 months, five patients (6.0%)
relapsed with a low-grade lymphoma at 10–22 months after the
remission without the evidence of reinfection; they were referred
for alternative treatment (operation or radiotherapy) (Figure 2).
Endoscopic appearances, location, depth of invasion and H. pylori
status were not associated with recurrence (Table 3). Cumulative
recurrence rate by Kaplan–Meyer survival analysis was 2.3, 7.7
and 9.3% at 1, 2 and 3 years after CR, respectively (Figure 3).
H. pylori has reinfected in 11 out of 99 patients (11.1%). But
there was no evidence of disease relapse and H. pylori was
eradicated in all of them.
DISCUSSION
Our study showed predominant distal stomach location of gastric
MALT lymphoma (67.7%). Although MALT lymphomas can occur
in any region of the stomach, they located most commonly in the
antrum and low body (Isaacson, 1996; Kim et al, 2001; Paik et al,
2002; Kahl, 2003), which reflects localisation of the highest
concentrations in colonised individuals of H. pylori organisms
and acquired lymphoid tissue (Wotherspoon, 1998). Interestingly,
in our analysis, the patients with treatment failure showed a
significantly greater frequency of proximal tumour location
(P¼0.001). Our possible explanation is that the pathophysiology
of proximal MALT lymphoma differs from that of distal
lymphoma; proximal lymphoma might also be associated with
H. pylori infection or may be H. pylori-independent autoimmune
gastritis, which is generally proximal in distribution (Dixon et al,
1996). Recent studies indicate that autoimmune gastritis may
derive from H. pylori infection and suggest that antibiotic resistant
Table 2 Risk factor analysis for non-response of MALT lymphoma
Characteristics
Non-response
(n¼15)
Response
(n¼84) P-value
Endoscopic appearance (%) NS
I: protruding, mass 3 (20.0) 6 (7.1)
II: granular, gastritis 1 (6.7) 18 (21.4)
III: depressed, erosion 6 (40.0) 44 (52.4)
IV: excavated, ulceration 4 (26.7) 11 (13.1)
V: mixed 1 (6.7) 5 (6.0)
Endoscopic location (%) 0.001
Proximal
a 10 (80.0) 19 (22.6)
Distal
b 5 (20.0) 62 (73.8)
Multifocal 0 (0) 3 (3.6)
Depth of gastric wall involvement
c (%)
Mucosa 5/15 (33.3) 40/66 (60.6)
Submucosa 6/15 (40.0) 22/66 (33.3) 0.064
Muscularis propria or beyond 4/15 (26.7) 4/66 (6.0) 0.031
MALT¼mucosa-associated lymphoid tissue.
aMid body, high body, fundus or cardia.
bAntrum, angle or low body.
cEvaluated by EUS in 67 patients and by histologic
examination of surgical specimen in 14 patients.
Endoscopic-bioptic follow-up
Op/RT
CCR (n=79)  Relapse (n=5)
99 patients with Hp-positive stage IE low grade gastric MALT
Eradication of Hp
CR (n=84) NC/PR (n=15)
Op/RT
Figure 2 Clinical response and follow-up of the 99 patients on the
basis of macroscopic and histologic findings. Hp¼Helicobacter pylori;
MALT¼mucosa-associated lymphoid tissue; CR¼complete remission;
NC¼no change; PR¼partial response; CCR¼continuous complete
remission.
Table 3 Risk factor analysis for recurrence of MALT lymphoma
Characteristics
Recurrence
(n¼5)
No recurrence
(n¼79) P-value
Endoscopic appearance (%) NS
I: protruding, mass 0 (0) 6 (7.6)
II: granular, gastritis 0 (0) 18 (22.8)
III: depressed, erosion 4 (80.0) 40 (50.6)
IV: excavated, ulceration 1 (20.0) 10 (12.7)
V: mixed 0 (0) 5 (6.3)
Endoscopic location (%) NS
Proximal
a 2 (40.0) 16 (20.3%)
Distal
b 3 (60.0) 60 (75.9%)
Multifocal 0 (0) 3 (3.8%)
Depth of gastric wall involvement
c (%) NS
Mucosa 3/5 (60.0) 45/75 (60.0)
Submucosa 2/5 (40.0) 25/75 (33.3)
Muscularis propria or beyond 0 (0) 5/75 (6.7)
Median time to CR (months) 3 3 NS
H. pylori reinfection (%) 0 (0) 11 (13.9) NS
MALT¼mucosa-associated lymphoid tissue.
aMid body, high body, fundus or cardia.
bAntrum, angle or low body.
cEvaluated by EUS in 66 patients and by histologic
examination of surgical specimen in 14 patients.
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(Negrini et al, 1991; Greiner et al, 1994). Hence, the subset of
H. pylori-eradicated MALT lymphomas in proximal stomach might
be associated with autoimmune-related or autonomous tumours in
patients with previous H. pylori gastritis, which do not respond to
H. pylori eradiation (Steinbach et al, 1999; Ruskone-Fourmestraux
et al, 2001). Our unpublished data for 27 patients with H. pylori-
negative gastric MALT lymphoma revealed the predominant
proximal location of lymphomas (62.9%), which suggests an
important role of H. pylori-independent pathogenesis in case of
proximal MALT lymphoma.
Although two large-scale German groups have shown the
long-term outcome of gastric MALT lymphoma after H. pylori
eradication (Fischbach et al, 2004; Wundisch et al, 2005),
reports about predictive factors for clinical response after
eradication therapy are rare. Our results might be valuable on the
development that endocsopic tumour location could be
used to derive a prognosis for remission following H. pylori
eradication.
The disease recurrence rate has been reported to vary from 7 to
12.5% in patients who once achieved CR (Neubauer et al, 1997;
Savio et al, 2000; Stolte et al, 2002; Fischbach et al, 2004). In the
update of the multicentre study of Fischbach et al (2004)
comprising 90 patients, 4.4% relapsed after a median follow-up
of 44 months. In another Italian series of Savio et al (2000)
involving 76 patients, 8% recurred during a median follow-up of 28
months. Our study showed that MALT lymphoma recurred in 6.0%
of patients with a median follow-up of 41 months. Cumulative
recurrence rate was 2.3, 7.7 and 9.3% at 1, 2 and 3 years after CR,
respectively. Recurrences were found at 10–22 months after
establishment of CR without the evidence of reinfection or
transformation to high-grade lymphoma. Endoscopic appearance,
location, depth of invasion and H. pylori status were not associated
with the recurrence.
At present, it is not known whether any specific characteristic of
the patient or of the lymphoma may predispose to a late relapse.
With respect to both the rate of recurrence and H. pylori
reinfection, Neubauer et al (1997) reported only one case of H. pylori
reinfection among four cases of local recurrence. Fischbach
et al (2004) also observed similar results of H. pylori reinfection,
one patient reinfected among four patients of relapse. Therefore, is
H. pylori probably not necessary for the lymphomas to relapse
after the remission? At the beginning, the low-grade B-cell clone is
still dependent on T-cell help (and thus susceptible to eradication
therapy), whereas, later in process of clonal evolution, H. pylori
infection and T-cell help may not be necessary (Hussell et al, 1993,
1996). The relapses may thus indicate that the patients had B-cell
lymphomas that had evolved from B-cell clones that were already
further progressed when the cure of H. pylori infection had been
performed. These data suggest that some relapses are a result of
the development of a lymphomatous clone that is independent of
the H. pylori-mediated antigenic drive.
In conclusion, H. pylori eradication as single therapy may be
appropriate for early-stage gastric MALT lymphoma, which leads
to a favourable long-term outcome, offering a real chance of cure.
In addition to depth of invasion, our results highlight the relevance
of the location of lesions as a predictive factor for tumoural
response. Until the clinical and the cellular characteristics of
H. pylori-dependent and H. pylori-independent tumours are better
defined, it would be prudent to pursue a cautious approach to
tailor the therapeutic strategy and follow-up of these patients.
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